english version
Основан в 1944 году




11 Февраль,2003 | Clozaril receives first indication to reduce risk of suicide - Schizophrenia

The antipsychotic drug Clozaril has received the U.S. Food and Drug Administration's first indication for reducing the risk of recurrent suicidal behavior in people with schizophrenia or schizoaffective disorder. Medical Letter on the CDC & FDA via NewsEdge Corporation : The antipsychotic drug Clozaril has received the U.S. Food and Drug Administration's (FDA) first indication for reducing the risk of recurrent suicidal behavior in people with schizophrenia or schizoaffective disorder. The decision was due in large part to an international clinical trial led by Vanderbilt's Dr. Herbert Meltzer, director of the division of psychopharmacology, that compared Clozaril to the more commonly prescribed drug Zyprexa. About 1% of the general population worldwide has schizophrenia or the closely related schizoaffective disorder - more than 2 million Americans. Over their lifetime, as many as 40% of people with these disorders will attempt suicide and 10% of them will die due to suicide. Annually in the United States, there are an estimated 40,000 serious suicide attempts among people with schizophrenia and 80,000 hospitalizations to prevent attempts. The lives of about 4,000 people with schizophrenia or schizoaffective disorder end by suicide. The Archives of General Psychiatry chronicled results of the International Suicide Prevention Trial (InterSePT), which show Clozaril, made by Novartis, reduced suicide and hospitalization for suicidal behavior among people with schizophrenia or schizoaffective disorder by 26% compared to Zyprexa, which could translate into an estimated 1000 U.S. lives saved each year. "There would be 10,000 fewer suicide attempts and 20,000 fewer hospitalizations annually, with greatly reduced costs for treatment and, of course, suffering to the individuals and their families," said Meltzer, the Bixler/Johnson/Mays Professor of Psychiatry, professor of pharmacology. "Suicide is the most feared outcome in the field of mental health treatment," Meltzer said. "The remarkable finding from InterSePT is that treatment with clozapine reduced suicidal events by up to a quarter over and above an established and effective antipsychotic." InterSePT began in 1998 and randomized 980 subjects at 67 sites in 11 countries, including 13 patients at Vanderbilt, to receive, on average, 275 mg per day of Clozaril or 17 mg per day of olanzapine (Zyprexa) for the duration of the 2-year study. Most people on Clozaril chose to continue it after the study ended. The drug reduced the number of suicidal behaviors (actions by a patient that put that patient at risk of death) compared to Zyprexa by 25%. The study also found that the amount of frequency of additional medications required to improve mood and suicidality was significantly less with Clozaril. Meltzer initiated the interest in the possibility that Clozaril had special effectiveness to reduce suicide in 1994 when he and a psychiatric research assistant, Dr. Ghadeer Okayli, found an 80% reduction in the number of people who made at least one suicide attempt among 88 people with schizophrenia who took the drug compared to the frequency in the 2 years before beginning treatment with Clozaril. Yet a fear of agranulocytosis, a potentially fatal complication that drastically decreases white blood cell counts, which Meltzer believes is disproportionate to the true risk, has prevented the drug from being widely used for patients who have persistent delusions and hallucinations, despite adequate trials with other antipsychotic drugs. The drug is now prescribed as a last resort, to about 5% of people with schizophrenia who have not benefited from Zyprexa, Risperdal, Geodone or Seroquel, the mainstays of current treatment for schizophrenia and schizoaffective disorder, which are prescribed, Meltzer estimated, to about 85% of the patients, the rest receiving the first generation of antipsychotics such as Haldol. Subsequent studies, including a key Boston University epidemiology study in 1995 of all 65,000 people who had been started on Clozaril, provided strong evidence for a marked decrease in suicide deaths for those who continued to take the drug. Meltzer proposed that Novartis fund a clinical trial to compare Clozaril to Zyprexa in order to establish its ability to reduce the risk of suicide. But the drug's patent was running out, opening the door for generics while closing a window of opportunity, in the form of economic incentives for the drug maker, to study the drug in a controlled clinical trial. Officials in the FDA's psychopharmacology division first balked, then changed their minds after they reconsidered the issue of "pseudospecificity." Until then, all new drugs for schizophrenia had to prove they were effective in treating delusions and hallucinations but not the totality of the symptoms and signs, which include cognitive impairment, negative symptoms (withdrawal, lack of motivation, anhedonia and diminished energy), mood and anxiety symptoms. Pseudospecificity eliminated the possibility that these other elements of the disease could be separate targets for treatment with drugs. "This idea represented an overvaluation of the gains to be achieved by treating psychosis," Meltzer said. "It was very apparent that was not the correct view. The various types of symptoms can be readily shown to be independent elements; beneath that they may stem from independent biology, including genetic factors." Presented with the results of the Clozaril study, the FDA acknowledged that the pseudospecificity perspective no longer governs its approach to approval of drugs for schizophrenia. "I believe this will have a great impact on stimulating more research to tackle other components of the illness, especially cognitive function, which I personally believe is the key feature of the illness that causes it to have such a devastating effect on work and social function," Meltzer said. In 1994 Meltzer and colleagues published the first evidence that any antipsychotic drug (they studied Clozaril) could significantly improve the cognitive impairment in schizophrenia. "Understanding this effect, which is shared to a greater or lesser extent by all the new antipsychotic drugs, is the major focus of our clinical and preclinical research," Meltzer said. His group includes Drs. Junji Ichikawa, Myung Lee and Tianlai Tang. The FDA's blessing gives Novartis the exclusive right to market Clozaril for people with schizophrenia at risk of suicide, which led to the company's funding of InterSePT. "It shows how good clinical, bedside observations can identify possible treatments, that can then lead to research collaborations between academia and industry," Meltzer said (Meltzer HY, Alphs L, Green AI, et al., "Clozapine treatment for suicidality in schizophrenia: International suicide prevention trial (InterSePT). Arch Gen Psychiatry, 2003;60(1):82-91). The study could lead to clinical trials of Clozaril to prevent suicide in people with bipolar disorder, a disease that affects as many people as schizophrenia but carries twice the rate of suicide deaths. It has also focused the attention of the American Psychiatric Association, which will soon publish new guidelines for treating suicidal patients in all diagnoses. This article was prepared by Medical Letter on the CDC & FDA editors from staff and other reports. <> << Copyright ©2003 NewsRx.com >>

11 Февраль,2003 | Research and Markets/ Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression

Mental disorders affect 44.3 million Americans in a given year. According to analysts the current global CNS therapeutics market is estimated at $40-55 billion, accounting for around 15% of the total global pharmaceuticals market. M2 PRESSWIRE via NewsEdge Corporation : Mental disorders affect 44.3 million Americans in a given year. According to analysts the current global CNS therapeutics market is estimated at $40-55 billion, accounting for around 15% of the total global pharmaceuticals market. From a geographical perspective, the US accounts for about two-thirds of this revenue. Affective disorders (including depression) and anxiety are amongst the 10 leading causes of disability in the US and other developed countries, affecting 9.5% and 15% of the US population respectively. Antidepressants, which are also used for the treatment of anxiety, are largely limited to the modulation of monoamine activity and new therapeutic opportunities have displayed limited mechanistic diversity. Despite the development of newer antidepressants undesirable side effects remain a problem as does the slow onset of activity. Furthermore, approximately 30% of the population do not respond to current therapies. Thus, although the anti-depressant/anxiolytic market is, in general, mature there is considerable therapeutic and commercial potential attached to the development of new molecules with novel mechanisms of action. In contrast, Alzheimer's disease occupies a small share of the total CNS market but is currently experiencing massive growth. Most current therapies or molecules in advanced development for Alzheimer's disease compensate for altered neurotransmission and depend heavily on the inhibition of cholinesterase or the modulation of cholinergic receptors. More recent advances include the move towards targeting amyloid and molecules that reduce production, accumulation or toxicity of this molecule are likely to stand side by side with cholinergic modifying molecules in future strategies for the treatment of Alzheimer's disease. Like the CNS market, drugs that have been launched for the treatment of hypertension are also massive revenue generators. Over the past decade, angiotensin II receptor antagonists have gradually been cutting into the market previously occupied by ACE inhibitors. Since the end of 2000, clinical trial data have been released suggesting that the angiotensin II receptor antagonists may have potential in a number of areas including diabetes and heart failure. As a result of the improved side-effect profile and expanded indications associated with the angiotensin II receptor antagonists this is the only class of antihypertensive compounds demonstrating significant growth. Current global sales are around $2 million and continue to increase by about 35% per year (based on sales figures from 1998-2001). Identification of additional indications is appealing since this will further boost sales. A body of data has been accumulating offering evidence that angiotensin receptor ligands may be of use in the treatment of depression, anxiety and cognitive disorders including Alzheimer's. Hence this class of molecule may bridge the two massive fields of CNS and cardiovascular disorders. LeadDiscovery in collaboration with Dr Paul Gard, global field leader in CNS actions of angiotensin ligands, has produced a dossier analyzing potential new indications for angiotensin II receptor antagonists. This report should allow companies previously involved in the development of this class as an approach to hypertension to significantly increase revenue potential. This report therefore overviews the clinical characteristics and current treatment options of the major CNS disorders for the benefit of cardiovascular disease experts. On the other hand this report also offers researchers in the field of CNS disorders the opportunity to assess the benefits of testing existing or future angiotensin receptor antagonists for antidepressant/anxiolytic or memory enhancing activity. Hence we offer a background to the angiotensin system for those with a focus on CNS disorders. A major part of this report describes in detail the evidence supporting an involvement of this system in the treatment of depression, anxiety and cognitive disorders including Alzheimer's disease. We conclude that angiotensin II type 1 receptor antagonist may be able to treat each of these disorders. Furthermore, agonists of the angiotensin type 4 receptor may be able to further stimulate cognitive function in Alzheimer's disease patients. Having established a proof of concept for using angiotensin receptor ligands for the treatment of CNS disorders, we then analyze the market and pharmaceutical activity surrounding these conditions. We identify those molecules on the market and in development for the treatment of depression, anxiety and Alzheimer's disease classifying each by pharmacological mode of action and by level of development. This shows that most molecules in development or on the market are limited to the modulation of monoamine activity. Through our trend analysis we identify which pharmacological classes are receiving growing attention and which are receiving decreasing interest. The results of these analyses support the claim that molecules with novel modes of action are currently in the spotlight. Likewise we identify angiotensin receptor ligands in development and classify them according to indication and level of development. This, and trend analysis clearly shows the level of maturity that angiotensin type 1 and type 2 receptor antagonists have reached. We profile each of these molecules and show the limited indications for angiotensin receptor ligands therefore supporting the conclusion that the revenue generated this class could be dramatically boosted by expanding indication to include CNS disorders. We further show that the level of pharmaceutical activity surrounding angiotensin type 4 receptors is virtually non-existent, thereby offering additional opportunities. Moreover our analysis of patent activity suggests that little early stage research is currently being reported with respect to both type 4 receptor agonists or CNS indications of type 1 antagonists. Because the angiotensin system has the potential to span the two diverse therapeutic areas of CNS and cardiovascular disorders there is considerable scope for industrial collaboration. Companies with expertise in hypertension may wish to collaborate with those that have previously focussed on the CNS. Thus we identify companies involved in both area and further identify those companies with a history of co-development/in-licensing so as to encourage collaboration. Although there is significant scope for broadening the indications of existing angiotensin receptor antagonist to include CNS disorders the possible benefits of further early stage development are also clear. For example companies with large libraries of angiotensin-related molecules may consider screening or molecular modelling approaches to identify those compounds more suited for treating depression, anxiety and Alzheimer's disease. Such molecules may be characterized by improved CNS penetration or they may have additional angiotensin type 4 receptor agonist activity. This reports therefore concludes by suggesting screening architectures that companies may wish to use to develop this most interesting, novel and potentially lucrative corner of the angiotensin system.. Dossier statistics: 19,952 words, overviews of clinical and economic aspects of depression, anxiety and Alzheimer's disease, overview of the angiotensin system, proof of concept and strategy for exploiting the angiotensin system for CNS disorders, an analysis of pharmaceutical activity surrounding antidepressant, anxiolytic and memory enhancing drugs, an analysis of pharmaceutical activity surrounding angiotensin receptor ligands including trend analyses, 21 drug profiles and patent activity, identification of companies involved in discovering and licensing molecules for the treatment of either CNS disorders or angiotensin receptor ligands, strategic advise for the exploitation of the angiotensin system for CNS disorders, recommended screening architecture and model selection. For a complete index of this report click on http://www.researchandmarkets.com/reports/10737 Report Index: 1. Summary 2. Background 3. Clinical && economic overviews Alzheimer's disease Depressive disorders Unipolar Disorders Bipolar Disorders Treatment strategies Reuptake inhibitors Tricyclic antidepressants 5-HT receptor antagonists Monoamine oxidase inhibitors Adrenoceptor antagonists Dopamine modulators Treatment guidelines Anxiety disorders Subtypes of anxiety disorders Panic disorder Phobic Disorders Agoraphobia Specific phobias Social Phobia Obsessive-Compulsive Disorder Posttraumatic Stress Disorder Generalized Anxiety Disorder 4. A role for angiotensin in CNS disorders The angiotensin system: A background Proof of concept Pharmacogenomic considerations 5. Disease incidence and market values 6. Current development activity surrounding the renin-angiotensin pathway and also anxiety, depression and Alzheimer's disease Angiotensin receptor ligands Drugs in development or on the market classified by phase and company Trend analysis Recent patent activity Drug profiles candesartan eprosartan irbesartan losartan valsartan telmisartan saralasin olmesartan CS-866CMB KRH-594 pratosartan EG-005 CS-088 TY-10721 ETRX-101 angiotensin-II Antidepressants/anxiolytics Drugs in development or on the market classified by pharmacology, phase and company Trend analysis Antidepressants/anxiolytics Drugs in development or on the market classified by pharmacology, phase and company Trend analysis Memory enhancers Drugs in development or on the market classified by pharmacology, phase and company Trend analysis Companies involved in angiotensin R&&D "Originators" Co-developers && In-licensers Companies involved in antidepressant/anxiolytic R&&D "Originators" Co-developers && In-licensers 7. Strategic analysis Which target for which condition? 8. Screening architecture and model selection 9. Selected Field Leader About the contributors to this report Dr Paul Gard (Senior Lecturer, University of Brighton): Dr Gard was educated at Nottingham and Aston Universities and has since occupied positions at the Schools of Pharmacy at Brighton and the Cental Institute of Technology, Wellington, New Zealand. Currently senior lecturer at the University of Brighton and Pharmacology Dr Gard is responsible for a research group focussing on behavioral pharmacology, particularly the behavioral effects of steroid and peptide hormones and in particular Dr Gard is one of the only global experts in the CNS effects of angiotensin. Secondary research interests include targeted drug delivery and drug delivery implants/devices. Dr Jon Goldhill: Dr Jon Goldhill has over 10 years of academic and industrial research experience including 5 years in middle management at the French pharmaceutical giants, Sanofi-Synthelabo. Focussing on a variety of indications including inflammatory disorders, GI disease, Urological conditions and cancer, Dr Goldhill was responsible for target identification and project development. Dr Goldhill is now CEO and chief analyst at LeadDiscovery and coordinates the identification of candidate drug discovery projects with industrial potential. Report Pricing: Hard Copy EUR 528 (US$ 493). Site Licence EUR 1,072 (US$ 1,002). ORDERING INFORMATION - FIVE EASY WAYS TO PLACE YOUR ORDER: ORDER ONLINE: To order this report please click on http://www.researchandmarkets.com/reports/10737 ORDER VIA EMAIL: mailto:orders researchandmarkets.com ORDER VIA FAX-BACK FORM: Click on http://www.researchandmarkets.com/reports/10737 Fax to +353 14957318 ORDER VIA POST: Click on http://www.researchandmarkets.com/reports/10737 Mail to Research and Markets Ltd., Guinness Centre, Taylors Lane, Dublin 8, Ireland ORDER VIA PHONE: Telephone: +353 868797580 About Research and Markets Ltd. Research and Markets Ltd. are Europe's largest resource for industry and market research reports. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends and forecasts. Major sectors covered include: Banking, Insurance, Pensions, Financial Services, Biotechnology, Genomics, General Business, Advertising, Marketing, Management, Personnel, Company Reports, Competitive Intelligence, Market Intelligence, Strategic Planning, Top 100 Company Lists, Computing, Advanced Technology, Hardware, Software, Construction, Engineering, Consumer, Personal Care, Clothing, Fashion, Household, Furniture, Country Reports (North American, South American, Europe, Africa, China, Asia Pacific, and Middle East), Demographics (Generational and Lifestyle), Energy, Natural Resources, Environmental, Gas, Oil, Power, Mining, Food, Beverage, Agriculture, Food Service, Government, Public Sector, Aerospace, Defence, Education, Healthcare, Medical Devices, Diagnostics, Hospital, Internet, E-Commerce, E-Business, IT Security, New Media, Manufacturing, Industry, Supply Chain and Logistics, Media, Entertainment, Broadcast, Cable, Gaming, Pharmaceuticals, Drug Delivery, Process Industry, Advanced Materials, Chemicals, Paper, Plastics, Retailing, Services Sector, Travel, Telecommunications, Networks, Satellite, Mobile and Wireless, Transport, Shipping, Automotive, and Aviation For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press researchandmarkets.com CONTACT: Holly Swift, Public Relations Manager, Research, Research and Markets Ltd. e-mail: holly.swift researchandmarkets.com ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info m2.com)). <> << Copyright ©2003 M2 Communications Ltd >>

04 Февраль,2003 | Диссертации:

04 Февраль,2003 | Myriad Genetics Discovers Major Depression Gene

- Discovery Triggers $1 Million Milestone Payment From Abbott - SALT LAKE CITY, Feb. 4 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. PR via NewsEdge Corporation : - Discovery Triggers $1 Million Milestone Payment From Abbott - SALT LAKE CITY, Feb. 4 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN), announced today the discovery of an important new gene named DEP1 that causes depression. The DEP1 gene will form the basis of a drug discovery and development program with Abbott Laboratories (NYSE: ABT), focusing on the development of an entirely new class of drugs to treat depression. The DEP1 gene discovery triggers a $1 million milestone payment to Myriad from Abbott. The DEP1 gene was discovered by genomic DNA analysis of over 400 Utah families with strong histories of major depression. Families were selected for multiple cases of major depression, which is a serious, chronic and often debilitating form of the disease, and early age at diagnosis of the disease. Three of the largest families contributing to the discovery of this gene each contained over 50 individuals with depression, all of whom participated in the study. The DEP1 gene acts in a novel pathway, not previously known to be involved in the cause of depression, and may lead to a novel class of anti-depressive therapeutics. The DEP1 pathway is independent of the pathway used by the dominant class of drugs currently used to treat depression, known as Selective Serotonin Re-uptake Inhibitors (SSRIs). "With the discovery of DEP1, Myriad and Abbott can initiate the drug development process from a strong starting point," said Peter Meldrum, President and CEO of Myriad Genetics, Inc. "We believe that the DEP1 gene and its associated pathway represent an exciting therapeutic opportunity." "We are truly delighted that Myriad has made such rapid progress on this dramatic scientific achievement," said Brian B. Spear, Ph.D., Director of Pharmacogenomics, Abbott Laboratories. "The identification of innovative new drugs for the treatment of depression is an important goal for Abbott's Neuroscience group. Abbott and Myriad scientists are working together to identify small molecule modulators of DEP1 using the state of the art drug discovery technologies available at both companies." The discovery of disease-causing genes provides an essential starting point for drug discovery, which is greatly expanded through the discovery of protein disease pathways. Using ProNet(r), Myriad's high-throughput protein interaction technology, the Company intends to identify critical protein interactions along the depression pathway. Proteins discovered in the depression pathway offer excellent opportunities as drug targets, while providing insight into the cause and possible treatment of the disease. The collaboration will focus on functional validation of these drug targets using biological analysis with innovative technologies for evaluating the importance of a particular protein in the cause of the disease. The combined use of Myriad's and Abbott's technologies provides a fast and effective means of drug target evaluation. Abbott's extensive experience in drug discovery and development should then enable rapid advancement of any product identified through the collaboration into clinical development. SSRIs include Prozac, Zoloft, and Paxil, and have rapidly become the first choice of many doctors for the treatment of depression. However, the drugs can take up to six weeks to provide relief and come with side effects. Accordingly, there is a substantial market for anti-depressant drugs and there are significant improvements possible versus current therapeutics. Myriad is pursuing a predictive medicine product from the DEP1 discovery, which could identify at-risk individuals who might then take preventive measures to avoid depression. Such a product may also prove useful in determining the class of anti-depressant used by physicians to treat diagnosed individuals as well as to differentiate the cause of depression on a medical genetic basis from the many diverse causes of the condition. Major depression affects about 12 percent of the population in the Western world at some point in life, making it one of the most common mental illnesses and the leading cause of disability worldwide. A very high proportion of sufferers remain undiagnosed and untreated. In Europe and the Unites States, sales figures indicate that as many as 100 million prescriptions are written per year, with sales growth of around 10 percent per year over the last five years. Much of this growth is due to the introduction of SSRIs, which are generally safer and better tolerated than older treatments. The SSRI class of drugs is now the most commonly prescribed type of anti-depressant with annual sales approaching $8 billion. Myriad Genetics, Inc. is a leading biopharmaceutical company focused on the development of novel healthcare products. The Company has established two wholly owned subsidiaries. Myriad Pharmaceuticals, Inc. develops and intends to market therapeutic products, and Myriad Genetic Laboratories, Inc. develops and markets proprietary predictive medicine and personalized medicine products. The Company has established strategic alliances with Abbott, Bayer, fDuPont, Eli Lilly, Hitachi, Novartis, Oracle, Pharmacia, Roche, Schering AG, Schering-Plough and Syngenta. Myriad's news and other information are available on the Company's Web site at www.myriad.com . The discussion in this news release includes forward-looking statements that are subject to certain risks and uncertainties, including statements relating to the role of the DEP1 gene in a novel pathway and its potential to lead to a novel class of anti-depressive therapeutics, the potential of the DEP1 gene and its associated pathway as an exciting therapeutic opportunity, Myriad's intent to identify critical protein interactions along the depression pathway, the focus of the collaboration between Myriad and Abbott, the ability of Abbott's experience to enable rapid advancement of products into clinical development, Myriad's pursuit of a predictive medicine product and the impact of such a product on at-risk individuals and medical diagnostics. Such statements are based on management's current expectations that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements, including, but not limited to uncertainties as to the extent of future government regulation of Myriad Genetics' business, uncertainties as to whether Myriad Genetics and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutics; the risk that markets will not exist for therapeutic compounds that Myriad Genetics develops or if such markets exist, that Myriad Genetics will not be able to sell compounds, which it develops, at acceptable prices. These and other risks identified in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2002. All information in this press release is as of February 4, 2003, and Myriad undertakes no duty to update this information unless required by law. SOURCE Myriad Genetics, Inc. -0- 02/04/2003 /CONTACT: William A. Hockett, Vice President of Corporate Communications of Myriad Genetics, Inc., +1-801-584-3600, bhockett myriad.com/ /Web site: http://www.myriad.com / (MYGN ABT) CO: Myriad Genetics, Inc.; Abbott Laboratories; Myriad Pharmaceuticals, Inc.; ST: Utah IN: HEA BIO MTC SU: MW-SK -- LATU026 -- 4573 02/04/2003 06:15 EST http://www.prnewswire.com <> << Copyright ©2003 PR Newswire >>

03 Февраль,2003 | Research in Denmark shows higher risk of schizophrenia in immigrants

A study has shown that immigrants in Denmark have a greater risk of developing schizophrenia. NORDIC BUSINESS REPORT via NewsEdge Corporation : A study has shown that immigrants in Denmark have a greater risk of developing schizophrenia. People who have moved to Denmark from Australia, Africa, the Middle East and Greenland have the highest risk of suffering from the disorder, while those from Scandinavia have the lowest, reported Reuters. A research team at the University of Lund in Sweden identified that immigrants were more than twice as likely as native Danes to develop schizophrenia. There was also found to be a greater risk in Danes who had lived abroad and returned to Denmark. The reasons for the findings are not known, but the researchers have suggested that future studies of schizophrenia should look at immigration rather than particular ethnic groups. ((Comments on this story may be sent to nbr.feedback nordicbusinessreport.com)) <> << Copyright ©2003 M2 Communications Ltd >>

03 Февраль,2003 | Net trafficking a boon for drug addicts

02/02/2003 Addicts of a powerful anti-depressant are using the Internet to exchange information that allows them easier access to the drug, the Mainichi has learned. Mainichi Daily News via NewsEdge Corporation : 02/02/2003 Addicts of a powerful anti-depressant are using the Internet to exchange information that allows them easier access to the drug, the Mainichi has learned. Web sites inform addicts of Ritalin, a powerful psychostimulant with effects similar to speed, how to fake prescriptions for the drug and offer clues to the identities of chemists who "easily" prescribe it. Addiction to the drug used mostly to treat Attention Deficit Hyperactivity Disorder is becoming rampant in Japan and authorities are being urged to crack down on its proliferation. Web sites dedicated to drug addicts began popping up as more people started using the Internet in the late '90s. Many sites were dedicated to Ritalin alone. Some Web pages list the initials of physicians who apparently prescribe the drug with few questions asked, as well as the name of the district where their clinic is located. Some sites offer information about how to trick a physician into diagnosing depression, while others provide information about methods to use the drug that will heighten its effects. Some contributors to sites, often calling themselves the "Ritalers,"outline details of their experience using the drug. Other sites have competitions to see who can consume the greatest quantity. The Internet is also proving to be a vital forum for Ritalin abusers, who use Web sites to arrange for drug swaps. "Many people use the Internet to get information about the types of drugs they want," a Tokyo woman addicted to Ritalin said. Growing numbers of forged prescriptions have also been reported. "With more color copying machines around, forgeries have been increasing for the past three years," a Tokyo Metropolitan Government health official said. In January last year, a boy used forgeries to secure from 10 drugstores massive amounts of Ritalin. He was sent to the family court for violating drug laws. As he had consumed 10 times the prescribed amount of the drug, he permanently damaged parts of his stomach and bowels. He was also plagued by hallucinations. Copyright 2003. All Rights Reserved. Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2003 Financial Times Limited, All Rights Reserved >>

31 Январь,2003 | Пополнение в разделе Неспециалистам

В разделе Для неспециалистов размещена брошюра "Психозы и их лечение"

29 Январь,2003 | Пополнение в разделе Пособия

В разделе пособия для врачей размещена лекция "Ларвированные депрессии" канд.мед.наук доц. кафедры психиатрии ЦОЛИУВ (ныне РМАПО) Видмановой Л.Н. В работе излагаются вопросы клиники, дифференциальной диагностики и терапии ларвированных депрессий

27 Январь,2003 | Пополнение в разделе Пособия

В разделе пособия для врачей размещена лекция "Аффективные психозы" Данное учебное пособие разработано сотрудниками кафедры психиатрии ЦОЛИУВ (ныне РМАПО) канд.мед.наук доц. Видмановой Л.Н. канд.мед.наук доц.Платоновой Т.П., канд.мед.наук асс. Суховским А.Л. канд.мед.наук асс.Жариковым М.Н.. В работе излагаются вопросы психопатологии, клиники, дифференциальной диагностики и терапии психических заболеваний, протекающих с аффективными расстройствами."

27 Январь,2003 | Mental Illness - More children are on prescription drugs for psychiatric disorders

The prevalence of psychotropic medication use among children and teenagers increased by two- to threefold from 1987 through 1996, according to a new study. Medical Letter on the CDC & FDA via NewsEdge Corporation : The prevalence of psychotropic medication use (drugs used to treat psychiatric disorders) among children and teenagers increased by two- to threefold from 1987 through 1996, according to a new study. Increased use of psychotropic medication (drugs normally used to treat psychiatric disorders, such as depression and other mood disorders, and attention deficit/hyperactivity disorder) for treating behavioral and emotional problems in children and adolescents has received widespread attention in the past decade. However, the extent of psychotropic medication treatment for youths receiving care in community settings has not been reliably reported. Julie Magno Zito, PhD, of the University of Maryland, Baltimore and colleagues examined changes in the psychotropic medication use for youths from 1987 to 1996. They analyzed data from nearly 900,000 youths younger than 20 years old enrolled in two U.S. health care systems, one in a midwestern state and one in a midatlantic state. The researchers found that the total use of psychotropic medications by youths increased 2- to 3- fold and included most classes of medication. They noted a rapid growth since 1991 in the use of drugs known as alpha-agonists, neuroleptics, and "mood stabilizer" anticonvulsants. The findings were published in the January 2003 issue of the Archives of Pediatric and Adolescent Medicine. The use of psychotropic drugs by youths on Medicaid almost always exceeded the rates of youths enrolled in health maintenance organizations (HMOs) by large margins, particularly alpha-agonists, neuroleptics, "mood stabilizer" anticonvulsants and lithium. Youths in HMOs had rates similar to Medicaid-insured youths for antidepressants and drugs known as hypnotic agents. Antidepressant medications were the second most commonly prescribed psychotropic medication by 1996, after stimulants. By 1996, the 10- to 14-year-old age group replaced the 5- to 9-year-olds as the largest group using psychotropic medication in the Medicaid populations studied. In the HMO population, 15- to 19-year-olds were the most prominent age group using psychotropics. "The 1-year period prevalence of psychotropic medication use grew to 6% of youths younger than 20 years, which represents a 2- to 3-fold increase in the decade from 1987 through 1996. Most of the temporal change occurred between 1991 and 1996. Medication classes generally showed a proportionally greater prevalence with increasing age, but 10- to 14-year-olds emerged as the Medicaid age group most likely to receive psychotropic medications while the 15- to 19-year-old group predominated among HMO medicated youths," wrote the authors (Arch Pediatr Adolesc Med, 2003;157:17-25; archpediatrics.com) This study was supported by a grant from the U.S. National Institute of Mental Health, Services Research and Clinical Epidemiology Branch, Bethesda, Maryland, and the Harold and Leila Y. Mathers Foundation, New York. In an accompanying editorial, Michael S. Jellinek, MD, of Massachusetts General Hospital, Boston, wrote, "The data reflect somewhat higher utilization rates for younger ages and possibly more serious disorders in Medicaid populations, which could support the hypothesis that mental illness in parents and the stressors of poverty add to the prevalence of child and adolescent psychiatric disorders in this subsample. An optimistic clinical perspective suggests that these data reflect a broader awareness of diagnostic criteria, less exclusive reliance on "talk therapy," and thoughtful efforts to extrapolate "off-label" from adult-based evidence to treat children and adolescents with serious mental health needs. "Given the scale of current psychotropic medication utilization, we have a responsibility to know what we are doing and the quality of our efforts. We need to ask ... this question: Are we prescribing the right psychotropic medications to the right children using the right treatment plan? Specifically, the work of Zito and colleagues reinforces our obligation to apply a quality assurance and research framework to our current pattern of utilization," Jellinek wrote. He concluded, "We need to have a more complete view in an ongoing, up-to-date time frame. We need a health plan-by-health plan quality assurance effort and a health services and basic research program" (Arch Pediatr Adolesc Med, 2003;157:14-16; archpediatrics.com). This article was prepared by Medical Letter on the CDC & FDA editors from staff and other reports. <> << Copyright ©2003 NewsRx.com >>

| Главная | Структура центра | История НЦПЗ | Совет молодых ученых | Костромские школы молодых ученых | Новости | Профсоюз | Правовые документы | Вакансии | О сайте | Научная работа | Научные отделы и лаборатории | Публикации сотрудников | Диссертационный совет | Авторефераты диссертаций | Музей НЦПЗ | Для научных сотрудников НЦПЗ | Центр коллективного пользования «Терапевтический лекарственный мониторинг» | Образовательная деятельность | Ординатура | Аспирантура | Дополнительное профессиональное образование | Студенческий научный кружок | Нормативные документы | Платные образовательные услуги | Информация для обучающихся в ординатуре и аспирантуре | Лечебный процесс | Клинические отделения | Условия и порядок стационирования | Прейскурант платных медицинских услуг | Перечень заболеваний | Отзывы о работе клиники | Клиника (фотогалерея) | Библиотека | Научная литература для специалистов | Материалы конференций | Авторефераты диссертаций | Пособия для врачей | Психометрические шкалы | Болезнь и творчество | Галерея | Журнал «Психиатрия» | Перечень тематических журналов, рекомендованных ВАК | Перечень тематических журналов в международных БД | РИНЦ | Russian Science Citation Index (RSCI) | Полезные ссылки | Журнал «Психиатрия» | Неспециалистам | Контакты